Economic Impact of Oral Therapies for Chronic Lymphocytic Leukemia—the Burden of Novelty
Purpose of Review
Small molecule tyrosine kinase inhibitors (TKIs) and BCL2 inhibitors are oral targeted therapies that have changed the treatment approach to patients with chronic lymphocytic leukemia (CLL). The aim of this review is to summarize the relevant literature on the economic impact of oral novel therapies for the treatment of CLL and discuss the underlying factors and suggested solutions for high drug prices.
The cost of therapy for CLL has increased substantially since the introduction of oral therapies. This increase in cost is caused by multiple factors including cost of drug development, alternate reimbursement patterns, lack of transparency, and lack of free market competition.
Oral therapies for CLL have dramatically increased costs for both patients and payers. Some solutions to overcome this include value-based pricing, transparency, and legal action that allow Medicare to negotiate drug prices with manufacturers.
KeywordsCLL Ibrutinib Idelalisib Venetoclax Drug costs Pharmacoeconomics, financial toxicity
Compliance with Ethical Standards
Conflict of Interest
Talal Hilal, Jeffrey A. Betcher, and Jose F. Leis declare that they have no conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major Importance
- 4.Fischer K, Cramer P, Busch R, Bottcher S, Bahlo J, Schubert J, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012;30(26):3209–16.CrossRefPubMedGoogle Scholar
- 8.Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
- 12.Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy N, Coutre S, et al. Updated efficacy including genetic and clinical subgroup analysis and overall safety in the phase 3 RESONATE trial of ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. Blood. 2014;124(21):3331.Google Scholar
- 14.Sharman JP, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, et al. Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: results from a phase 3, randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2014;32(15_suppl):7011.Google Scholar
- 19.Medicare Medicare Plan Finder. Available from: https://www.medicare.gov/find-a-plan/questions/home.aspx.
- 22.Dusetzina SB, Huskamp HA, Winn AN, Basch E, Keating NL. Out-of-pocket and health care spending changes for patients using orally administered anticancer therapy after adoption of state parity Laws. JAMA Oncol. 2017;Google Scholar
- 24.Henry J. Kaiser Family Foundation: The Medicare Part D Prescription. Drug Benefit 2017. Available from: https://www.kff.org/medicare/fact-sheet/the-medicare-prescription-drug-benefit-fact-sheet/.
- 26.• Chen Q, Jain N, Ayer T, Wierda WG, Flowers CR, O'Brien SM, et al. Economic burden of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States. J Clin Oncol. 2017;35(2):166–74. This study projects future cost burden of CLL with the use of oral targeted therapies. CrossRefPubMedGoogle Scholar
- 27.Jain N, Chen Q, Ayer T, O'Brien SM, Keating M, Wierda W, et al. Prevalence and economic burden of chronic lymphocytic leukemia (CLL) in the era of oral targeted therapies. Blood. 2015;126(23):871.Google Scholar
- 40.NCCN Evidence Blocks. Available from: https://www.nccn.org/evidenceblocks/.
- 42.The Florida Senate: House Bill 351. Available from: https://www.flsenate.gov/Session/Bill/2018/00351.
- 43.Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Available from: https://www.congress.gov/bill/108th-congress/house-bill/1.